Brief: Abbott Secures CE Mark For Dual Glucose-Ketone Sensing Technology For Diabetes Patients
27/05/2026 14:24
BRIEF-Abbott Secures CE Mark For Dual Glucose-Ketone Sensing Technology For Diabetes Patients May 27 (Reuters) - Abbott Laboratories ABT.N:
SECURES CE MARK FOR WORLD'S FIRST DUAL GLUCOSE-KETONE SENSING TECHNOLOGY FOR PEOPLE WITH DIABETES
Source text: ID:nPn1m4nD6a
Further company coverage: ABT.N
((Reutersbriefs@thomsonreuters.com;))
Recent news on Abbott Laboratories
See all newsPress Digest: Wall Street Journal - June 29
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports (updated)
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
Factbox: Major deals involving US drugmakers and biotechs over the past decade
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test